ID

28370

Beschrijving

The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living. The secondary objective of the study is to explore dose and exposure response and the clinical treatment effects of natalizumab versus placebo in acute ischemic stroke on the following: measures of independence, activities of daily living, neurologic function, quality of life, cognition, and safety and tolerability. https://clinicaltrials.gov/ct2/show/study/NCT02730455.

Link

https://clinicaltrials.gov/ct2/show/study/NCT02730455

Trefwoorden

  1. 08-01-18 08-01-18 -
Houder van rechten

Biogen

Geüploaded op

8 januari 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility criteria ACTION 2 Acute Ischemic Stroke NCT02730455

Eligibility criteria ACTION 2 Acute Ischemic Stroke NCT02730455

Key Inclusion Criteria
Beschrijving

Key Inclusion Criteria

Age 18 to 80 Years
Beschrijving

Age

Datatype

boolean

Clinical diagnosis of supratentorial acute ischemic stroke defined by LKN ≤24 hours prior to study treatment initiation
Beschrijving

diagnosis of stroke

Datatype

boolean

Score of 5 to 23 points, inclusive, on the NIHSS at Screening for subjects initiating treatment ≤9 hours from LKN
Beschrijving

Note: NIHSS eligibility must be confirmed within 60 minutes prior to randomization

Datatype

boolean

Score of 5 to 15 points, inclusive, on the NIHSS at Screening for subjects initiating treatment >9 to ≤24 hours from LKN
Beschrijving

Note: NIHSS eligibility must be confirmed within 60 minutes prior to randomization

Datatype

boolean

Prior to index stroke, patient was able to perform basic activities of daily living without assistance: dressing, eating, walking, bathing, and using the toilet
Beschrijving

basic activities of daily living

Datatype

boolean

For those subjects who underwent a cranial MRI, there is at least 1 acute infarct with a diameter of ≥2 cm on baseline brain diffusion-weighted imaging
Beschrijving

acute infarct diameter MRI

Datatype

boolean

Key Exclusion Criteria
Beschrijving

Key Exclusion Criteria

Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and available acute imaging studies performed under the standard of care
Beschrijving

brainstem or cerebellar stroke

Datatype

boolean

Presence of acute intracranial hemorrhage on acute brain CT or MRI. However, petechial hemorrhages of ≤1 cm are not exclusionary
Beschrijving

acute intracranial hemorrhage

Datatype

boolean

Severe stroke defined by imaging criteria based on either one of the following: Alberta Stroke Program Early CT (ASPECT) score of 0 to 4 based on head CT or Acute infarct volume on MRI diffusion weighed imaging greater than or equal to 70 mL
Beschrijving

Severe stroke

Datatype

boolean

Seizure at the onset of stroke
Beschrijving

Seizure

Datatype

boolean

Known history of prior treatment with natalizumab
Beschrijving

natalizumab

Datatype

boolean

Known history of active viral hepatitis B or C
Beschrijving

hepatitis B or C

Datatype

boolean

Signs and symptoms of active or acute infection
Beschrijving

infection

Datatype

boolean

Similar models

Eligibility criteria ACTION 2 Acute Ischemic Stroke NCT02730455

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Key Inclusion Criteria
Age
Item
Age 18 to 80 Years
boolean
diagnosis of stroke
Item
Clinical diagnosis of supratentorial acute ischemic stroke defined by LKN ≤24 hours prior to study treatment initiation
boolean
NIHSS score within 9 hours of last known normal
Item
Score of 5 to 23 points, inclusive, on the NIHSS at Screening for subjects initiating treatment ≤9 hours from LKN
boolean
NIHSS score 9-24 hours after last known normal
Item
Score of 5 to 15 points, inclusive, on the NIHSS at Screening for subjects initiating treatment >9 to ≤24 hours from LKN
boolean
basic activities of daily living
Item
Prior to index stroke, patient was able to perform basic activities of daily living without assistance: dressing, eating, walking, bathing, and using the toilet
boolean
acute infarct diameter MRI
Item
For those subjects who underwent a cranial MRI, there is at least 1 acute infarct with a diameter of ≥2 cm on baseline brain diffusion-weighted imaging
boolean
Item Group
Key Exclusion Criteria
brainstem or cerebellar stroke
Item
Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and available acute imaging studies performed under the standard of care
boolean
acute intracranial hemorrhage
Item
Presence of acute intracranial hemorrhage on acute brain CT or MRI. However, petechial hemorrhages of ≤1 cm are not exclusionary
boolean
Severe stroke
Item
Severe stroke defined by imaging criteria based on either one of the following: Alberta Stroke Program Early CT (ASPECT) score of 0 to 4 based on head CT or Acute infarct volume on MRI diffusion weighed imaging greater than or equal to 70 mL
boolean
Seizure
Item
Seizure at the onset of stroke
boolean
natalizumab
Item
Known history of prior treatment with natalizumab
boolean
hepatitis B or C
Item
Known history of active viral hepatitis B or C
boolean
infection
Item
Signs and symptoms of active or acute infection
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial